Exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. Our first commercial product, COMETRIQ® (cabozantinib), received its initial regulatory approval in late 2012. We are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer.

METEOR Phase 3 Pivotal Trial Results

Exelixis released positive top-line results for METEOR, the phase 3 pivotal trial of cabozantinib in metastatic renal cell carcinoma, on July 20, 2015.

View Press Release
Listen to Webcast


Aug 28 2015 12:49pm EDT
6.09 0